Search

This document explores the effectiveness of venetoclax-combination regimens for treating relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Myeloid malignancies, such as TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), have historically had poor treatment responses and survival rates. While hypomethylating agents (HMAs) and venetoclax combination therapy have been used, outcomes remain suboptimal. The study focuses on patients with AML who received venetoclax-combination therapy after treatment with azacitidine (AZA) and magrolimab, finding that a significant number achieved complete remission or partial hematologic recovery. However, more research is needed to fully understand the outcomes of this treatment approach. [Extracted from the article]

Objective: This pilot clinical trial investigated solution-focused brief therapy (SFBT) for psychological distress among adolescent and young adult (AYA) patients with cancer in China. Methods: Fifty Chinese AYA patients diagnosed with cancer were randomized into the treatment group (SFBT) and control group (active control). Psychological distress was measured by the brief symptom inventory and hope was measured by the Herth-Hope-Index. Treatment effects were analyzed using analysis-of-covariance and between-group small-sample-size corrected Hedges' g. Results: The results indicated that SFBT resulted in a significant reduction in the psychological distress and improvement in hope of AYA patients with cancer. Analyses of the 4-week posttreatment score suggest the short-term sustainability of SFBT for psychological distress among AYAs diagnosed with cancer. Conclusions and Implications. This study has demonstrated that SFBT's impact is statistically significant and clinically meaningful. The inclusion of positive emotions, i.e., hope, as part of the investigation also highlighted the significance of promoting positive emotions among AYA patients with cancer. [ABSTRACT FROM AUTHOR]

Cancer survivors suffer from health deficits caused by their disease and treatment. This study conducted a systematic review and meta-analysis on how, and to what extent, cognitive-behavioral therapy (CBT) impacts functional health outcomes in cancer survivors. We searched 7 electronic databases, 91 published review articles, and 4 professional websites for eligible randomized and non-randomized controlled trials focusing on cancer survivors. We included 95 studies published between 1986 and 2021. Risk of bias across studies was low overall. We identified an overall statistically significant treatment effect size across functional health categories, d = 0.391, p < 0.001, and significant moderators associated with CBT's treatment effect, i.e., treatment phase and type of comparison. CBT was effective at improving functional health outcomes of cancer survivors, regardless of therapy delivery modality or number of cancer diagnoses patients had, but not for newly diagnosed patients or those currently benefiting from an active comparator intervention. [Display omitted] • Cognitive behavioral therapy (CBT) improves functional health in cancer survivors. • CBT has the strongest treatment effect on insomnia, followed by fatigue. • CBT is effective regardless of therapy delivery modality. • CBT is effective during all treatment phases except for those newly diagnosed. • CBT is superior to treatment as usual but not superior to other active comparators. [ABSTRACT FROM AUTHOR]